Mutein IL-2 attenuates antibody-mediated rejection in murine kidney transplantation
August 5, 2025 | World Transplant Congress
Mutein IL-2 attenuates antibody-mediated rejection in murine kidney transplantation
Five Strategies to Use IL-2 Muteins to Expand Foxp3+ Treg Cells and Promote Long-term Cardiac and Renal Allograft Survival in Naïve and Sensitized Recipients
August 5, 2025 | World Transplant Congress
Five Strategies to Use IL-2 Muteins to Expand Foxp3+ Treg Cells and Promote Long-term Cardiac and Renal Allograft Survival in Naïve and Sensitized Recipients
An IL-2 Mutein (VIS171) Induces Regulatory T Cells and Prolongs Survival in a Rhesus Kidney Transplant Model
August 5, 2025 | World Transplant Congress
An IL-2 Mutein (VIS171) Induces Regulatory T Cells and Prolongs Survival in a Rhesus Kidney Transplant Model
Selective Enrichment and Functional Preservation of Treg Cells During IL-2 Mutein-Mediated Expansion and Contraction
August 2, 2025 | World Transplant Congress
Selective Enrichment and Functional Preservation of Treg Cells During IL-2 Mutein-Mediated Expansion and Contraction
C5aR1 inhibition ameliorates DGF in a DCD porcine kidney auto-transplantation model
August 2, 2025 | World Transplant Congress
C5aR1 inhibition ameliorates DGF in a DCD porcine kidney auto-transplantation model
Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study
June 6, 2025 | 62nd ERA Congress
Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study
Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity
June 5, 2025 | 62nd ERA Congress
Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity
Preclinical Development of VIS171 – A Novel Modified IL-2 Safely and Selectively Upregulates Regulatory T Cells to Treat Autoimmune Diseases
September 6, 2024 | Promise of Interleukin-2 Therapy Conference
Preclinical Development of VIS171 – A Novel Modified IL-2 Safely and Selectively Upregulates Regulatory T Cells to Treat Autoimmune Diseases
Modified-IL-2 (VIS171) to Preferentially Induce Regulatory T Cells in Nonhuman Primates
September 6, 2024 | Promise of Interleukin-2 Therapy Conference
Modified-IL-2 (VIS171) to Preferentially Induce Regulatory T Cells in Nonhuman Primates
Tissue-resident ST2+ regulatory T cells promote cardiac transplant tolerance induced by a mutein IL-2
June 2, 2024 | American Transplant Congress
Tissue-resident ST2+ regulatory T cells promote cardiac transplant tolerance induced by a mutein IL-2
- 1
- 2
- 3
- …
- 5
- Next Page »